EPIX (ESSA Pharma Inc.) Earnings per share growth rate in current year

EPIX (essapharma.com) - company brandmark

ESSA Pharma Inc. (EPIX) is developing high-precision therapies to block tumor receptors, focusing on N-terminal domain inhibition in cases of resistance to standard treatment. The year-over-year earnings per share dynamics on GURU.Markets capture the current trend, where 0.00 records a new level. The company's strategy relies on its own pipeline tests and targeted alliances with the largest pharma behemoths.

EPIX - essapharma.com Earnings growth in current year over the range 07/04/2022 - 10/25/2025

Analytical breakdowns and data insights for company essapharma.com (EPIX)

- price and consensus price forecast:
Stock Quotes ESSA Pharma|EPIX - Analyst Consensus Forecast
- business market valuation indicators:
Market Value ESSA Pharma|EPIX - Total Company Value
- balance sheet equity data:
Equity per Share ESSA Pharma|EPIX - Book Capitalization|Market-to-Book Ratio essapharma.com|EPIX - Aggregate Company Assets
- debt and liquidity details:
Total Debt to Capital Coefficient ESSA Pharma Inc.|EPIX - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient ESSA Pharma|EPIX - Company Aggregate Debts|Debts to Book Capitalization ESSA Pharma|EPIX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings ESSA Pharma|Critical Liquidity Ratio essapharma.com
- earnings and market ratios statistics:
EPIX - Net Profit|Expected Net Income ESSA Pharma Inc.|EPIX - P/E Multiple|Forward P/E Multiple ESSA Pharma|EPIX - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation ESSA Pharma|EPIX - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months ESSA Pharma|EPIX - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth essapharma.com|EPIX - Net earnings per share growth this year|Expected earnings per share trend next year ESSA Pharma Inc.
Fundamental valuation:ESSA Pharma Inc.
Mass-produced product of ESSA Pharma Inc

Analyzing the annual earnings per share growth rate for the biotech issuer ESSA Pharma Inc. (EPIX), we assess the dynamics of net income per share. This metric measures the percentage change in EPS, neutralizing time gaps between quarterly reports. The current value of 0.00 reflects high capital sensitivity to operating expenses. For a company without commercial revenue, this indicator marks the cash burn rate prior to the publication of Phase 1/2 results. A negative or unstable curve confirms high pipeline risks.

Key competitors

Net earnings per share growth this year Merus NV|IMMP (Immutep Limited ADR) - Earnings growth in current year|Earnings per share growth rate in current year Anixa Bio ANIX|Earnings per share growth in current year Atossa Therapeutics (ATOS)|contexttherapeutics.com - Earnings per share growth this year|Earnings growth in current year MRSN (Mersana Therapeutics, Inc.)|BriaCell Therapeutics Corp. (BCTX) - Earnings per share growth rate in current year|QTI - Earnings per share growth in current year